Concepedia

Reena Wang

RW

5

Publications

161

Citations

5

H-Index

2014

Active since

Affiliations

Bristol-Myers Squibb (United States)(Current)

GlaxoSmithKline (United States)

University of Oxford

Saitama Medical University

Harvard University

Reena Wang is an author at Bristol-Myers Squibb (United States) specializing in antibody engineering, medicine, and clinical trials.

Top concepts

Publications per year

2014–2023

5

Publications

5

Single-Dose Pharmacokinetics and Safety of Daclatasvir in Subjects with Renal Function Impairment

Τushar Garimella, Reena Wang, Wen‐Lin Luo et al. · Antiviral Therapy · 2014 · 49 citations · Full text

Pharmacokinetic, Pharmacodynamic, and Safety Profile of a Novel Anti-CD28 Domain Antibody Antagonist in Healthy Subjects

Rong Shi, Marek Honczarenko, Sean X. Zhang et al. · The Journal of Clinical Pharmacology · 2016 · 43 citations · Full text

, , +20

Anti-GM-CSF otilimab versus tofacitinib or placebo in patients with active rheumatoid arthritis and an inadequate response to conventional or biologic DMARDs: two phase 3 randomised trials (contRAst 1 and contRAst 2)

Roy Fleischmann, Désirée van der Heijde, Vibeke Strand et al. · Annals of the Rheumatic Diseases · 2023 · 29 citations · Full text

Anti-GM-CSF otilimab versus sarilumab or placebo in patients with rheumatoid arthritis and inadequate response to targeted therapies: a phase III randomised trial (contRAst 3)

Peter C. Taylor, Michael E. Weinblatt, Iain B. McInnes et al. · Annals of the Rheumatic Diseases · 2023 · 27 citations · Full text

A Randomized Trial in Healthy Subjects to Assess the Bioequivalence of an Atazanavir/Cobicistat Fixed-Dose Combination Tablet versus Administration as Separate Agents

Heather Sevinsky, Xiaolu Tao, Reena Wang et al. · Antiviral Therapy · 2014 · 13 citations

Rows per page

1–5 of 5